

Robert Weissert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3015353/publications.pdf>

Version: 2024-02-01

131
papers

11,171
citations

47006

47
h-index

29157

104
g-index

136
all docs

136
docs citations

136
times ranked

11093
citing authors

#	ARTICLE	IF	CITATIONS
1	A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 387-401.	27.0	2,314
2	Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis. <i>American Journal of Pathology</i> , 2000, 157, 267-276.	3.8	854
3	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	13.7	684
4	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	3.6	494
5	Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology. <i>Brain Pathology</i> , 1998, 8, 681-694.	4.1	472
6	Cytokine Storm in COVID-19 – Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. <i>Frontiers in Immunology</i> , 2020, 11, 1648.	4.8	370
7	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
8	Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. <i>Neurology</i> , 2011, 77, 580-588.	1.1	286
9	Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease. <i>Rejuvenation Research</i> , 2011, 14, 3-16.	1.8	225
10	MHC haplotype-dependent regulation of MOG-induced EAE in rats.. <i>Journal of Clinical Investigation</i> , 1998, 102, 1265-1273.	8.2	224
11	Acute Neuronal Apoptosis in a Rat Model of Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2001, 21, 6214-6220.	3.6	213
12	Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Brain</i> , 2001, 124, 1114-1124.	7.6	159
13	FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. <i>Brain Research Bulletin</i> , 2007, 74, 307-316.	3.0	155
14	Methylprednisolone Increases Neuronal Apoptosis during Autoimmune CNS Inflammation by Inhibition of an Endogenous Neuroprotective Pathway. <i>Journal of Neuroscience</i> , 2003, 23, 6993-7000.	3.6	154
15	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology</i> , The, 2012, 11, 420-428.	10.2	152
16	Mechanisms and Time Course of Neuronal Degeneration in Experimental Autoimmune Encephalomyelitis. <i>Brain Pathology</i> , 2004, 14, 148-157.	4.1	149
17	EAE: imperfect but useful models of multiple sclerosis. <i>Trends in Molecular Medicine</i> , 2011, 17, 119-125.	6.7	145
18	Cladribine. <i>Clinical Neuropharmacology</i> , 2011, 34, 28-35.	0.7	140

#	ARTICLE	IF	CITATIONS
19	Escalating immunotherapy of multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1329-1339.	3.6	129
20	Identification of HLA-DRâ€‘bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. <i>Journal of Clinical Investigation</i> , 2007, 117, 3576-3582.	8.2	112
21	Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. <i>European Journal of Immunology</i> , 1998, 28, 3329-3335.	2.9	108
22	Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2012, 69, 1259.	4.5	97
23	Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. <i>Brain</i> , 2001, 124, 953-961.	7.6	94
24	Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis. <i>Journal of Experimental Medicine</i> , 1998, 187, 1543-1548.	8.5	93
25	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	1.4	86
26	Peripheral Blood Mononuclear Cells: Isolation, Freezing, Thawing, and Culture. <i>Methods in Molecular Biology</i> , 2014, 1304, 53-61.	0.9	85
27	Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2015, 6, 322.	4.8	84
28	T Cell Epitopes of Human Myelin Oligodendrocyte Glycoprotein Identified in HLA-DR4 (DRB1*0401) Transgenic Mice Are Encephalitogenic and Are Presented by Human B Cells. <i>Journal of Immunology</i> , 2001, 167, 7119-7125.	0.8	79
29	Cortical Demyelination Can Be Modeled in Specific Rat Models of Autoimmune Encephalomyelitis and Is Major Histocompatibility Complex (MHC) Haplotype-Related. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1137-1142.	1.7	77
30	Progressive multifocal leukoencephalopathy. <i>Journal of Neuroimmunology</i> , 2011, 231, 73-77.	2.3	72
31	Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. <i>Neurology</i> , 2004, 63, 2381-2383.	1.1	69
32	The Immune Pathogenesis of Multiple Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 857-866.	4.1	67
33	Functional Connectivity in Multiple Sclerosis: Recent Findings and Future Directions. <i>Frontiers in Neurology</i> , 2018, 9, 828.	2.4	66
34	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 33-45.	1.8	65
35	Naturally Presented Peptides on Major Histocompatibility Complex I and II Molecules Eluted from Central Nervous System of Multiple Sclerosis Patients. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2090-2101.	3.8	64
36	Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. <i>European Journal of Immunology</i> , 2008, 38, 2401-2411.	2.9	63

#	ARTICLE	IF	CITATIONS
37	Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. <i>Clinical Immunology</i> , 2009, 133, 353-363.	3.2	63
38	Linkage Analysis of Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis in the Rat Identifies a Locus Controlling Demyelination on Chromosome 18. <i>Human Molecular Genetics</i> , 1999, 8, 2183-2190.	2.9	62
39	Tolerance induction by bone marrow transplantation in a multiple sclerosis model. <i>Blood</i> , 2005, 106, 1875-1883.	1.4	62
40	Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. <i>Acta Neuropathologica</i> , 2007, 113, 195-203.	7.7	62
41	Ciliary Neurotrophic Factor Protects Retinal Ganglion Cells from Secondary Cell Death During Acute Autoimmune Optic Neuritis in Rats. <i>Brain Pathology</i> , 2004, 14, 378-387.	4.1	61
42	Oligoclonal bands predict multiple sclerosis in children with optic neuritis. <i>Annals of Neurology</i> , 2015, 77, 1076-1082.	5.3	61
43	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	3.0	60
44	Daytime sleepiness versus fatigue in patients with multiple sclerosis: A systematic review on the Epworth sleepiness scale as an assessment tool. <i>Sleep Medicine Reviews</i> , 2017, 32, 95-108.	8.5	58
45	Hyperphosphorylation and Aggregation of Tau in Experimental Autoimmune Encephalomyelitis. <i>Journal of Biological Chemistry</i> , 2004, 279, 55833-55839.	3.4	55
46	MHC Class II-Regulated Central Nervous System Autoaggression and T Cell Responses in Peripheral Lymphoid Tissues Are Dissociated in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2001, 166, 7588-7599.	0.8	52
47	Suppressive DNA Vaccination in Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis Involves a T1-Biased Immune Response. <i>Journal of Immunology</i> , 2003, 170, 1806-1813.	0.8	47
48	Differential Expression of Sonic Hedgehog Immunoreactivity During Lesion Evolution in Autoimmune Encephalomyelitis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 404-411.	1.7	46
49	Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice. <i>Journal of Neuroimmunology</i> , 2006, 173, 23-34.	2.3	46
50	Î² Kinase 2/Î² Deficiency Controls Expansion of Autoreactive T Cells and Suppresses Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2007, 179, 179-185.	0.8	46
51	Differential Processing of Autoantigens in Lysosomes from Human Monocyte-Derived and Peripheral Blood Dendritic Cells. <i>Journal of Immunology</i> , 2005, 175, 5940-5949.	0.8	45
52	Analysis of Autoreactive CD4 T Cells in Experimental Autoimmune Encephalomyelitis after Primary and Secondary Challenge Using MHC Class II Tetramers. <i>Journal of Immunology</i> , 2004, 172, 2878-2884.	0.8	43
53	Enhanced Glucocorticoid Receptor Signaling in T Cells Impacts Thymocyte Apoptosis and Adaptive Immune Responses. <i>American Journal of Pathology</i> , 2007, 170, 1041-1053.	3.8	43
54	High Immunogenicity of Intracellular Myelin Oligodendrocyte Glycoprotein Epitopes. <i>Journal of Immunology</i> , 2002, 169, 548-556.	0.8	42

#	ARTICLE	IF	CITATIONS
55	Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 1689-1694.	7.1	40
56	IL-3 promotes the development of experimental autoimmune encephalitis. <i>JCI Insight</i> , 2016, 1, e87157.	5.0	39
57	Editorial: Telemedicine During and Beyond COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 662617.	2.7	39
58	Immunoglobulin isotypes reveal a predominant role of type 1 immunity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001, 121, 120-125.	2.3	38
59	The Use of Clinically Approved Small Particles of Iron Oxide (SPIO) for Labeling of Mesenchymal Stem Cells Aggravates Clinical Symptoms in Experimental Autoimmune Encephalomyelitis and Influences Their In Vivo Distribution. <i>Cell Transplantation</i> , 2008, 17, 923-941.	2.5	38
60	Late-Onset Myasthenia Gravis: Follow-up of 113 Patients Diagnosed after Age 60. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 777-780.	3.8	34
61	Genetics of rat neuroinflammation. <i>Journal of Neuroimmunology</i> , 2000, 107, 191-200.	2.3	32
62	Genetic analysis of inflammation, cytokine mRNA expression and disease course of relapsing experimental autoimmune encephalomyelitis in DA rats. <i>Journal of Neuroimmunology</i> , 1997, 80, 31-37.	2.3	31
63	MHC Gene Related Effects on Microglia and Macrophages in Experimental Autoimmune Encephalomyelitis Determine the Extent of Axonal Injury. <i>Brain Pathology</i> , 2002, 12, 287-299.	4.1	30
64	Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant. <i>Journal of Neuroinflammation</i> , 2015, 12, 169.	7.2	30
65	Congenetic mapping confirms a locus on rat chromosome 10 conferring strong protection against myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. <i>Immunogenetics</i> , 2001, 53, 410-415.	2.4	29
66	Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. <i>Journal of Neuroimmunology</i> , 2003, 144, 28-37.	2.3	27
67	The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. <i>Human Immunology</i> , 2009, 70, 540-542.	2.4	27
68	Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 52-57.	2.3	27
69	T cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 transgenic mice during experimental autoimmune encephalomyelitis. <i>Clinical Immunology</i> , 2004, 111, 53-60.	3.2	26
70	Diffusion Abnormality in Balo's Concentric Sclerosis: Clues for the Pathogenesis. <i>European Neurology</i> , 2005, 53, 42-44.	1.4	26
71	Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood stem cell transplantation. <i>Blood</i> , 2002, 100, 2679-2680.	1.4	25
72	CD8+ Phagocyte Recruitment in Rat Experimental Autoimmune Encephalomyelitis. <i>American Journal of Pathology</i> , 2003, 163, 1517-1524.	3.8	25

#	ARTICLE	IF	CITATIONS
73	Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders. <i>Frontiers in Immunology</i> , 2017, 8, 336.	4.8	25
74	Identification of gene expression patterns critically involved in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1211-1220.	2.4	24
75	Treatment of active secondary progressive multiple sclerosis with treosulfan. <i>Journal of Neurology</i> , 2007, 254, 884-889.	3.6	23
76	The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases. <i>Frontiers in Nutrition</i> , 2018, 5, 133.	3.7	23
77	Allelic variations in rat MHC class II binding of myelin basic protein peptides correlate with encephalitogenicity. <i>International Immunology</i> , 1999, 11, 1981-1988.	4.0	22
78	Influence of Formal Education on Cognitive Reserve in Patients with Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2016, 7, 46.	2.4	22
79	Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003â€“2015. <i>Frontiers in Neurology</i> , 2019, 10, 613.	2.4	22
80	Gene expression analysis of normal appearing brain tissue in an animal model for multiple sclerosis revealed grey matter alterations, but only minor white matter changes. <i>Journal of Neuroimmunology</i> , 2008, 205, 10-19.	2.3	21
81	Emerging role of white matter lesions in cerebrovascular disease. <i>European Journal of Neuroscience</i> , 2021, 54, 5531-5559.	2.6	20
82	Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. <i>Multiple Sclerosis Journal</i> , 2008, 14, 153-158.	3.0	19
83	Myelin-Reactive Type B T Cells and T Cells Specific for Low-Affinity MHC-Binding Myelin Peptides Escape Tolerance in HLA-DR Transgenic Mice. <i>Journal of Immunology</i> , 2008, 181, 3202-3211.	0.8	18
84	Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-Barré Syndrome. <i>Journal of Immunology</i> , 2009, 182, 4432-4438.	0.8	18
85	Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 46-51.	1.9	17
86	Leukoaraiosis severity and postâ€“reperfusion outcomes in acute ischaemic stroke: A metaâ€“analysis. <i>Acta Neurologica Scandinavica</i> , 2021, , .	2.1	17
87	NCF1 gene and pseudogene pattern: association with parasitic infection and autoimmunity. <i>Malaria Journal</i> , 2008, 7, 251.	2.3	15
88	Effects of Sport Climbing on Multiple Sclerosis. <i>Frontiers in Physiology</i> , 2017, 8, 1021.	2.8	15
89	Autoantigen Conformation Influences Both B- and T-cell Responses and Encephalitogenicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 17206-17213.	3.4	14
90	Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination. <i>Experimental Neurology</i> , 2012, 237, 70-77.	4.1	14

#	ARTICLE	IF	CITATIONS
91	The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 140, 177-187.	2.3	13
92	Exogenous Schwann Cells Migrate, Remyelinate and Promote Clinical Recovery in Experimental Auto-Immune Encephalomyelitis. <i>PLoS ONE</i> , 2012, 7, e42667.	2.5	13
93	The Effect of Coffee and Caffeine Consumption on Patients with Multiple Sclerosis-Related Fatigue. <i>Nutrients</i> , 2020, 12, 2262.	4.1	12
94	Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2001, 113, 202-211.	2.3	11
95	Specific immune complexes augment in vitro acetylcholine receptor-specific T cell proliferation. <i>Neurology</i> , 1993, 43, 583-583.	1.1	11
96	Polygenic control of autoimmune peripheral nerve inflammation in rat. <i>Journal of Neuroimmunology</i> , 2001, 119, 166-174.	2.3	10
97	Modulation of neuronal activity by the endogenous pentapeptide QYNAD. <i>European Journal of Neuroscience</i> , 2003, 18, 2697-2706.	2.6	10
98	Peptide motif for the rat MHC class II molecule RT1.Da: similarities to the multiple sclerosis-associated HLA-DRB1*1501 molecule. <i>Immunogenetics</i> , 2005, 57, 69-76.	2.4	10
99	Characterization of the encephalitogenic immune response in a model of multiple sclerosis. <i>European Journal of Immunology</i> , 2008, 38, 299-308.	2.9	10
100	Altered tumor growth factor β mRNA expression is associated with thymectomy-related clinical remission in myasthenia gravis. <i>Journal of the Neurological Sciences</i> , 1997, 151, 49-55.	0.6	9
101	Transfer of myelin-specific cells deviated in vitro towards IL-4 production ameliorates ongoing experimental allergic neuritis. <i>Clinical and Experimental Immunology</i> , 2001, 123, 112-118.	2.6	9
102	CDR3 sequence preference of TCRBV8S2+ T cells within the CNS does not reflect single amino acid dependent avidity expansion. <i>Journal of Neuroimmunology</i> , 2005, 166, 47-54.	2.3	9
103	MHC Class II Isotype- and Allele-Specific Attenuation of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2004, 173, 2792-2802.	0.8	8
104	Actively Induced Experimental Autoimmune Encephalomyelitis in Rats. <i>Methods in Molecular Biology</i> , 2014, 1304, 161-169.	0.9	8
105	Major histocompatibility complex haplotype RT1av1 is associated with relapsing/remitting experimental autoimmune encephalomyelitis. <i>Transplantation Proceedings</i> , 1997, 29, 1686-1689.	0.6	7
106	Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 563645.	4.8	7
107	Treatment with atacept enhances neuronal cell death in a rat model of optic neuritis. <i>Journal of Neuroimmunology</i> , 2014, 268, 58-63.	2.3	6
108	Lack of pathogenicity of immunodominant T and B cell determinants of the nicotinic acetylcholine receptor μ -chain. <i>Journal of Neuroimmunology</i> , 2004, 152, 44-56.	2.3	5

#	ARTICLE	IF	CITATIONS
109	MHC and non-MHC gene regulation of disease susceptibility and disease course in experimental inflammatory peripheral neuropathy. <i>Journal of Neuroimmunology</i> , 2004, 155, 73-84.	2.3	5
110	The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1587-1590.	2.8	5
111	Multiple Sclerosis. <i>Methods in Molecular Biology</i> , 2016, 1304, v-vi.	0.9	5
112	Experimental Autoimmune Encephalomyelitis (EAE): Lesion Visualization on a 3 Tesla Clinical Whole-body System after Intraperitoneal Contrast Injection. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2004, 176, 1549-1554.	1.3	4
113	Statins: a revised appraisal for potential additional future treatment indications. <i>Arthritis Research and Therapy</i> , 2012, 14, 121.	3.5	4
114	Experimental Autoimmune Encephalomyelitis. , 2012, , .		4
115	Increased immune reactivity to central nervous system-derived naturally presented peptides in patients with active multiple sclerosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 694-696.e7.	2.9	4
116	Fulminant Acute Ascending Hemorrhagic Myelitis Treated with Eculizumab. <i>Frontiers in Neurology</i> , 2017, 8, 345.	2.4	4
117	Suspected Perinatal Depression Revealed to be Hereditary Diffuse Leukoencephalopathy with Spheroids. <i>Journal of Movement Disorders</i> , 2017, 10, 59-61.	1.3	4
118	Immunogenicity of Torpedo acetylcholine receptor in the context of different rat MHC class II haplotypes and non-MHC genomes. <i>Immunogenetics</i> , 2004, 56, 61-64.	2.4	3
119	Myelin oligodendrocyte glycoprotein has a dual role in T cell autoimmunity against central nervous system myelin. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731663099.	1.0	3
120	Brain atrophy in acute ischaemic stroke patients treated with reperfusion therapy: a systematic review. <i>Acta Radiologica</i> , 2021, , 028418512110604.	1.1	3
121	Upregulated Retinal Neurofilament Expression in Experimental Optic Neuritis. <i>Neuro-Ophthalmology</i> , 2022, 46, 215-219.	1.0	3
122	Benefit of ELISpot in early diagnosis of tuberculous meningoencephalitis: Case report and literature review. <i>ENeurologicalSci</i> , 2015, 1, 51-53.	1.3	2
123	Experimental Autoimmune Encephalomyelitis - Models, Disease Biology and Experimental Therapy. , 2012, , .		2
124	Differential response to treatment of relapsing-remitting multiple sclerosis with IFN- β : is there a dichotomy into T-helper-1 and -17 driven disease?. <i>Future Neurology</i> , 2010, 5, 481-484.	0.5	1
125	PO10-TU-40 Mode of action (MoA) of cladribine tablets: activity in lymphocytes and implications for treatment of multiple sclerosis (MS). <i>Journal of the Neurological Sciences</i> , 2009, 285, S206.	0.6	0
126	Neurodegeneration in MS and NMO: The Eye and the Blood. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-2.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Activation of encephalitogenic T cells in a MOG-induced marmoset EAE model is regulated by linked suppression. Journal of Neuroimmunology, 2014, 275, 58.	2.3	0
128	Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response. Frontiers in Immunology, 2017, 8, 1218.	4.8	0
129	We should focus more on finding therapeutic targets for the non-inflammatory damage in MS – No. Multiple Sclerosis Journal, 2018, 24, 1274-1276.	3.0	0
130	T Cell Epitopes of the Acetylcholine Receptor and the Pathogenesis of Myasthenia Gravis. , 1997, , 119-126.		0
131	Neuroimmunology and Neurological Manifestations of COVID-19. , 0, , .		0